It was my understanding that one of the Chavi sourced posts stated it was submitted in May. After researching more I see that it was in the May CHAVI update report and the paper was stated to be submitted in 2009. So I guess it could still be imminent then. I apologize for this confusion.
I'm getting over anxious to see this info. I'm trying to decide whether to buy more now (while I believe its still very, very cheap) or wait to see about the split issue. Its my opinion that the highest probability of moving this stock lies with the solid news that the anti-viral effect of Bavi is "add your won adjectives here". The only other anti-viral information that Peregrine has is tied up in secrecy with the DTRA work.
I feel fairly confident that the Duke paper will provide the information I'm seeking, one way or the other. Now that I know that the paper may have been submitted as early as January, I realize that there is still a very good chance that the info will come out before the NASDAQ deadline.
I would have thought that the cancer news provided to date would have moved this stock up. I think the cancer news has been tremendous to date. The problem with cancer is that the goal is long term survival or cure. The fact is that this info takes a long time to prove itself and there is nothing we can do about that. Unless we get news like constantly increasing ORRs or more CRs before the NASDAQ deadline I don't think the cancer news is going to be the big motivating news to move this stock before the deadline.
I love hearing the cancer updates. There hasn't been one disappointment yet. The only disappointment I've seen with the cancer trials is the lack of a complete cure for the entire population by the end of the first stage's treatment cycle (and I know that to be a very unrealistic expectation).
I'm not holding my breath for any partnering news. Mostly because I personally don't want to see a partnership until we can't possibly proceed on our own any more, while at the same time having progressed these anti-viral and anti-cancer products so far through the trials that it becomes unquestioned that Bavi is the supreme anti-cancer and anti-viral platform for the future.
I am very greedy too. I try to balance that with my conscience all the time. I do this by telling myself that as long as Peregrine's livelihood is tied to Bavi, Bavi will have no better, more motivated advocate than Peregrine. Only if BP pays HUGE bucks will it be motivated to ensure Bavi's progress. A pre-mature deal will risk getting this drug to market at all and those who need it most would then suffer the most (how's that for a rationalization).
Personally I think this company has a great future. I've only been invested in it for two years but at least I've weathered the worst of it (I hope I don't jinx anything here). Sorry for the long post. Just wanted to get my views across.
